Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience

BACKGROUND: Low‐molecular‐weight heparin has been the preferred treatment of cancer‐associated thrombosis (CAT); however, emerging data support the use of direct oral anticoagulants (DOACs). OBJECTIVES: The Memorial Sloan Kettering Cancer Center Clinical Pathway has served as the institutional guide...

Descripción completa

Detalles Bibliográficos
Autores principales: Soff, Gerald A., Mones, Jodi, Wilkins, Cy, Devlin, Sean, Haegler‐Laube, Eva, Wills, Jonathan, Sarasohn, Debra M., Juluru, Krishna, Singer, Michael, Miao, Yimei, Batista, Jeanette, Mantha, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles: Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611365/
https://www.ncbi.nlm.nih.gov/pubmed/31294321
http://dx.doi.org/10.1002/rth2.12215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611365/
https://www.ncbi.nlm.nih.gov/pubmed/31294321
http://dx.doi.org/10.1002/rth2.12215

Ejemplares similares